In its quest for new ways to use bio-engineered bacteria to manipulate the immune system as a superior tool for fighting cervical and other cancers as well as infectious diseases, Advaxis collaborates with top research centers around the world.
• National Cancer Institute - Advaxis works with the Institute's Gynecologic Oncology Group to conduct a multi-center, Phase 2 clinical trial of ADXS-HPV immunotherapy, for patients with recurrent or refractory cervical cancer who have failed prior cytotoxic therapy.
• University of Pennsylvania - Advaxis works with the University's School of Veterinary Medicine, collaborating with Dr. Nicola Mason to study the ADXS-HER2 construct for the treatment of canine osteosarcoma in large breed companion dogs.
• Cancer Research UK - The UK organization, dedicated to cancer research, is conducting a clinical trial to investigate the use of ADXS-HPV for the treatment of head and neck cancer.
• Montefiore Medical Center - Advaxis is working with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.
• National Cancer Institute - Advaxis has a Collaborative Research and Development Agreement (CRADA) with the Vaccine Section of the Institute for the development of Advaxis immunotherapies.
• Wistar Institute - Advaxis is collaborating with the Wistar Institute in Pennsylvania to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy.
• University of British Columbia - Advaxis is collaborating with the laboratory of Dr. Tobias Kollmann to develop Advaxis immunotherapies for the treatment of infectious disease and to develop new dosage forms.
• Karolinska Institutet - Advaxis is collaborating with the laboratory of Professor Marianne van Hage at the Karolinska Institutet in Stockholm, Sweden, to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases.
For additional information, visit Advaxis.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net